(MENAFN- PR Newswire)
Imidex's technology is a Front-End Patient Acquisition Tool for Healthcare Providers Targeting Early Lung Cancer Detection, Achieving 83% Sensitivity in Identifying Lung Nodules in Chest X-rays.
DENVER, Nov. 29, 2024 /PRNewswire/ -- Imidex, a leader in developing artificial intelligence solutions for medical imaging, today announced plans to sell the company at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago. At the center of this announcement is VisiRad XR®, an FDA 510(k)-cleared AI solution that uniquely enables both incidental lung nodule detection and community-wide screening for lung nodules.
Continue Reading
Imidex's goal is to address a critical gap in the healthcare system, particularly for patients with early-stage lung cancer who might otherwise go undiagnosed until later stages. Current screening protocols often focus on high-risk populations undergoing CT scans, leaving as many as half of the stage 1 and stage 2 lung cancer patients undetected. By leveraging routine chest X-rays, VisiRad XR® serves as a powerful front-end patient acquisition tool, empowering radiologists and healthcare providers to improve their accuracy at detecting often-missed critical findings.
Imidex to sell company and patented, FDA-cleared lung nodule algorithm at RSNA conference in Chicago, December 2-4
Post thi
"Imidex is transforming how lung cancer is detected, ensuring more patients are diagnosed at a treatable stage," said Wes Bolsen, CEO of Imidex. "We want to get the leading algorithm, cleared for detecting nodules as small as 6mm, into the hands of a company that can more rapidly deploy the solution to radiologists and healthcare providers."
The company's robust capabilities are built upon one of the largest annotated chest X-ray datasets in the United States, encompassing both lung nodules and seven additional findings: devices, effusion, fracture, pneumothorax, consolidation, cardiomegaly, and atelectasis. This expansive dataset underscores the valuable assets that Imidex's acquirer will be able to build upon.
Additionally, Imidex's intellectual property portfolio was significantly strengthened with broad patents issued in the Summer of 2024. These patents establish a formidable IP fence, offering the future acquirer strong protection against competitors seeking to enter the U.S. AI lung cancer detection market.
Imidex invites interested parties to meet with representatives during RSNA 2024.
Meetings will be held from December 2–4 at McCormick Place in Chicago. This announcement highlights a rare opportunity to acquire a pioneering company with transformative FDA-cleared technology, a robust patent portfolio, and a proven impact on lung nodule detection.
Website:
SOURCE IMIDEX
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN29112024003732001241ID1108939481
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.